CROs/Service Providers

PPD launches apprenticeship for Clinical Research Associates

Thursday, March 23, 2017

Pharmaceutical Product Development (PPD) launched a clinical research associates (CRAs) apprenticeship program targeted to military veterans and military service members with medical backgrounds who are transitioning to the civilian workforce. PPD’s initiative, the first CRA apprenticeship program registered with the U.S. Department of Labor, will begin in North Carolina, Texas and California in the first quarter of this year.

[Read More]

Thermo Fisher Scientific, Cell and Gene Therapy Catapult collaborate

Tuesday, March 21, 2017

To help address the challenges surrounding supply chain management for cell and gene therapy around the globe, Thermo Fisher Scientific announced a collaboration with the Cell and Gene Therapy Catapult (CGT Catapult) to provide developers with both the manufacturing capability and distribution, logistics and storage capacity needed to create a seamless supply chain to accelerate cell and gene therapy development and commercialization.

[Read More]

Metrion Biosciences, Concept Life Sciences launch ion channel drug discovery service

Wednesday, March 15, 2017

Metrion Biosciences, a specialist ion channel CRO and drug discovery company, and Concept Life Sciences, the business formed in 2014 to break into the international integrated discovery & development and analytical markets, have announced a strategic alliance to provide pharmaceutical clients with fully integrated medicinal chemistry and biology research services for ion channel drug discovery.

[Read More]

BioreclamationIVT acquires TransCell Science

Thursday, March 9, 2017

BioreclamationIVT has acquired TransCell Science, a privately held CRO specializing in the use of primary cells for phenotypic screening assays. With its scientific expertise in the areas of cell culture and cell-based assays, clients have looked to TransCell as a partner in developing protocols and conducting studies that provide pertinent data for their research programs. The output from such studies enables “go” or “no go” decisions with a higher level of confidence at a much earlier time point within the drug discovery process and greatly reduces the chance of downstream failure.

[Read More]